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Abstract: Many women experience bothersome vasomotor and vaginal symptoms during the 
menopausal transition. Decreasing levels of estrogens during menopause are also associated 
with reduced bone density and an increased risk of osteoporosis. Combined estrogen/progestin 
therapy (hormone therapy) effectively treats menopausal symptoms and prevents bone loss, but 
has been associated with some safety and tolerability concerns. A novel menopausal therapy is 
the tissue selective estrogen complex, which pairs a selective estrogen receptor modulator with 
one or more estrogens. In preclinical studies, the tissue selective estrogen complex partnering 
bazedoxifene (BZA) with conjugated estrogens (CE) antagonized stimulation of breast and 
endometrial tissue, reduced vasomotor instability, and preserved bone mass in rat and mouse 
models. The specific attributes seen with BZA/CE were different from those observed with 
other selective estrogen receptor modulator/estrogen pairings. BZA/CE has undergone clinical 
evaluation in the Phase III Selective estrogens, Menopause, And Response to Therapy (SMART) 
trials in postmenopausal women with an intact uterus. Of the various doses of BZA/CE evaluated, 
BZA 20 mg/CE 0.45 mg and 0.625 mg were associated with a low incidence of endometrial 
hyperplasia (,1%) similar to placebo, and showed significant improvements in hot flushes and 
vulvar/vaginal symptoms and increases in bone mineral density. BZA 20 mg/CE 0.45 mg and 
0.625 mg were associated with a low incidence of breast-related adverse events and demonstrated 
no difference from placebo in age-related changes in mammographic breast density. Both BZA/
CE doses showed a favorable tolerability profile, with no increases in uterine bleeding or breast 
tenderness, and had positive effects on metabolic parameters and quality of life. BZA/CE may 
be a promising alternative to hormone therapy for the treatment of menopausal symptoms and 
prevention of osteoporosis in nonhysterectomized postmenopausal women.
Keywords: tissue selective estrogen complex, bazedoxifene, conjugated estrogens, menopause, 
osteoporosis, vasomotor symptoms
Introduction
Postmenopausal women may experience a variety of symptoms associated with a 
decline in the level of estrogens.1 Vasomotor symptoms (VMS), such as hot flushes, are 
reported by 60%–85% of women during menopause.2 Vulvar/vaginal atrophy (VVA; 
symptoms of which may include vaginal dryness, irritation, soreness, or dyspareunia, 
and increases in urinary frequency, urgency, or incontinence) is reported by 50% of 
postmenopausal women.3 The menopausal transition may also accelerate the rate of 
bone loss, leading to susceptibility to postmenopausal osteoporosis and associated 
fractures.4–6 In addition to the burden of the reduced quality of life (QoL) imposed by 
menopausal symptoms, the financial costs of menopausal treatments, lost productivity, 
and increased health care expenses present a significant economic burden.7
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Many menopausal therapies are designed to treat individual 
symptoms.5 Topical estrogens or estradiol preparations such 
as creams, pessaries, tablets, and vaginal rings have been 
shown to be effective for the treatment of VVA.8 Tibolone 
has been shown to effectively treat VMS and VVA.9 
Bisphosphonates, selective estrogen receptor modulators 
(SERMs), parathyroid hormone, estrogens, and calcitonin 
are approved pharmacologic agents for the prevention and/
or treatment of postmenopausal osteoporosis.10
The most common treatments for postmenopausal women 
who experience moderate-to-severe VMS along with other 
menopausal symptoms are estrogens and combined estrogen/
progestin or estradiol/progestin therapy (hormone therapy 
[HT]).11 HT options include conjugated estrogens (CE)/
medroxyprogesterone acetate (MPA), sequential estrogens/
trimegestone, drospirenone/estradiol, estradiol/norethindrone, 
and transdermal estradiol/norethindrone acetate.5 In addition to 
effectively treating VMS and VVA, estrogen monotherapy and 
HT have also shown efficacy in preventing postmenopausal 
osteoporosis and are considered comprehensive treatment 
options.11 Although the addition of progestins to estrogens provides 
protection against endometrial stimulation for postmenopausal 
women with a uterus,12,13 HT has been associated with some 
safety and tolerability concerns, including cardiovascular risk, 
breast stimulation, and irregular vaginal bleeding.11,14,15
A novel therapy currently under investigation for the 
treatment of menopausal symptoms and the prevention of 
osteoporosis is the tissue selective estrogen complex (TSEC), 
which pairs a SERM with one or more estrogens.16 SERMs 
have estrogen receptor (ER) agonist or antagonist activities 
depending on the target tissue.17,18 The goal of TSEC is to 
combine the established efficacy of estrogens on VMS, 
VVA, and bone with the protective effects of a SERM on the 
uterus and breast.16 The first TSEC in clinical development 
partners bazedoxifene (BZA) with CE. BZA is a SERM that 
has demonstrated efficacy in the treatment and prevention 
of osteoporosis with a favorable endometrial/breast safety 
profile in postmenopausal women. This review provides an 
overview of the key preclinical findings for BZA/CE and 
describes the results from the Phase III clinical trials of 
BZA/CE in postmenopausal women with an intact uterus. 
The emerging role of TSEC in the current treatment paradigm 
for postmenopausal women is also discussed.
Preclinical studies with BZA/CE
In vitro studies
BZA/CE was developed with the goal of achieving an 
optimal balance of ER agonist and antagonist activities. 
Berrodin evaluated BZA/CE, raloxifene (RLX)/CE, and 
lasofoxifene (LAS)/CE in a multiplex biochemical assay.19 
In this assay, BZA interacted with some cofactor peptides 
and not others, while LAS and RLX inhibited all of the 
peptides to which they were exposed. These results suggest 
that when combined with CE, BZA is more likely to exhibit 
tissue-selective effects than LAS or RLX.19 In a cell-based 
system of Michigan Cancer Foundation-7 (MCF-7) breast 
cancer cells, the global gene expression pattern associated 
with BZA/CE differed from that with RLX/CE or LAS/CE. 
The expression profile of BZA/CE was more similar to 
that with CE alone; in contrast, RLX/CE and LAS/CE had 
profiles that were similar to the SERM alone.19 In another 
study, the proliferation of MCF-7 cells was not induced by 
BZA/CE, although some proliferation was observed with 
RLX/CE and LAS/CE.20 These findings support a distinct 
activity profile for BZA/CE among other TSEC pairings in 
displaying agonist activity in some tissues and antagonist 
activity in others.19
In vivo studies
The effects of BZA, RLX, and LAS (all 3 mg/kg) combined 
with estradiol (1 µg/kg) on breast and uterine tissues have 
been evaluated in ovariectomized (OVX) mice.21 In this 
model, BZA, RLX, and LAS prevented estradiol-induced 
increases in uterine wet weight (P , 0.05 vs estradiol 
alone). BZA was a more effective antagonist of estradiol-
induced increases in uterine wet weight than RLX or LAS 
(P , 0.05 vs estradiol/RLX or estradiol/LAS). In addition, 
treatment with BZA and RLX, but not LAS, reduced the 
estradiol-induced mammary gland end bud proliferation and 
all three SERMs significantly reduced the estradiol-induced 
expression of GPR105 and INDO mRNA markers of uterine 
and breast stimulation, respectively (P , 0.05 vs estradiol 
alone for both markers).21
In a study of mature OVX rats treated with BZA/CE 
daily for 6 weeks,16 the combination of BZA 3.0 mg/kg with 
CE 0.5, 1.0, or 2.5 mg/kg prevented CE-induced increases 
in uterine wet weight. Treatment with BZA 0.1, 0.3, 1.0, 
or 3.0 mg/kg/CE 2.5 mg/kg and BZA 3.0 mg/kg/CE 0.5, 
1.0, 2.5, or 5.0 mg/kg resulted in higher proximal tibia 
total bone mineral density (BMD) than with vehicle control 
(P , 0.01). CE 10.0 mg/kg significantly reduced tail skin 
temperature versus vehicle control in the morphine-addicted 
rat model of vasomotor instability. Addition of BZA 0.3, 3.0, 
or 10.0 mg/kg to CE 10.0 mg/kg maintained this response 
(P , 0.05 vs vehicle control). BZA 3.0 mg/kg/CE 0.5, 
1.0, 2.5, or 5.0 mg/kg was also associated with significant 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
130
Komm and MirkinInternational Journal of Women’s Health 2012:4
decreases in serum total cholesterol compared with vehicle 
control (P , 0.01).16
The endometrial and breast effects of BZA/CE were 
further evaluated in OVX sexually immature mice.22 The 
minimal doses of BZA, RLX, and LAS that prevented 
CE-induced increases in uterine wet weight were determined 
to be BZA 2 mg/kg, RLX 10 mg/kg, and LAS 2 mg/kg. At 
these doses, the combinations of BZA and RLX with CE 
3 mg/kg were more effective than LAS 2 mg/kg/CE 3 mg/kg 
at preventing CE-induced increases in uterine wet weight 
(P , 0.05). BZA was a better antagonist of CE-induced 
breast stimulation than RLX or LAS (P , 0.05), as measured 
by mammary gland amphiregulin mRNA expression. In an 
analysis of mammary gland whole mounts using these same 
SERM/CE doses, BZA/CE reduced the number of ductal 
branch points, a measure of ductal tree complexity, to a level 
similar to that with vehicle control and significantly lower 
than RLX/CE or LAS/CE (P , 0.05).22
The skeletal effects of BZA/CE were evaluated in 
OVX rats treated daily for 1 year with BZA 0.3 mg/kg, CE 
2.5 mg/kg, or BZA 0.1, 0.3, or 1.0 mg/kg/CE 2.5 mg/kg.23 
BMD of the lumbar spine and right proximal femur was 
significantly increased at 1 year compared with OVX 
control for all doses of BZA/CE (P , 0.05). Similarly, 
trabecular BMD of the proximal tibia metaphysis was 
significantly increased at 1 year with all doses of BZA/CE 
compared with OVX control (P , 0.05). Histomorphometry 
evaluation showed that all doses of BZA/CE prevented the 
OVX-induced changes in static and dynamic parameters 
of the cortical compartment of the tibia and cancellous 
compartment of the L1 and L2 vertebrae. BZA 0.1, 
0.3, and 1.0 mg/kg/CE 2.5 mg/kg reduced uterine wet 
weights in a dose-dependent manner. BZA 0.1, 0.3, and 
1.0 mg/kg/CE 2.5 mg/kg were associated with significant 
decreases in serum total cholesterol compared with OVX 
control (P , 0.05).
Overall, preclinical studies have shown that BZA/CE 
effectively prevents stimulation of uterine and breast tissue 
in a variety of in vitro and in vivo models. BZA/CE has 
also been shown to preserve bone mass, reduce vasomotor 
effects, and reduce serum total cholesterol in OVX rats. 
These findings in preclinical models suggest that BZA/CE 
has the potential to effectively treat menopausal symptoms, 
prevent bone loss, and have favorable effects on the lipid 
profile while maintaining breast and endometrial safety 
in nonhysterectomized postmenopausal women. BZA/CE 
has been subsequently evaluated in a series of Phase III 
clinical trials.
Clinical studies with BZA/CE
The efficacy and safety of BZA/CE have been evaluated 
in multicenter, randomized, double-blind, placebo- and 
active-controlled, Phase III studies referred to as the 
Selective estrogens, Menopause, And Response to Therapy 
(SMART) trials (Table 1). These studies were conducted in 
postmenopausal women with an intact uterus, and assessed 
the efficacy, safety, and tolerability of BZA/CE in treating 
menopausal symptoms and preventing osteoporosis. 
Published reports of the Phase III studies of BZA/CE are 
described in this review.
The 2-year SMART-1 trial (n = 3544) was conducted to 
evaluate the incidence of endometrial hyperplasia at 1 year 
in generally healthy women aged 40 to 75 years.24–27 Other 
endpoints included the effects of BZA/CE on BMD, bone 
turnover markers, VMS, VVA, safety, metabolic parameters, 
uterine bleeding, and QoL. The treatments evaluated in this 
trial were BZA 10, 20, and 40 mg/CE 0.45 and 0.625 mg, 
RLX 60 mg, and placebo.
The SMART-2 trial (n = 332)28 evaluated the change from 
baseline in frequency and severity of hot flushes at 12 weeks 
in women aged 40 to 65 years who reported at least seven 
moderate-to-severe hot flushes per day (or $50 per week) at 
baseline. The SMART-3 trial (n = 664)29 evaluated changes in 
four measures of VVA (the proportion of vaginal superficial 
cells, the proportion of parabasal cells, vaginal pH, and 
severity of the most bothersome VVA symptom) in women 
aged 40 to 65 years who had at least one moderate-to-severe 
symptom of VVA at baseline. Secondary endpoints included 
effects on sleep (SMART-2 only), QoL, and safety. The 
treatments evaluated in these trials were BZA 20 mg/CE 0.45 
and 0.625 mg, BZA 20 mg (SMART-3 only), and placebo.
efficacy on menopausal symptoms
vasomotor effects
The efficacy of BZA/CE on VMS was evaluated by 
measuring the frequency and severity of hot flushes in 
response to treatment. In the SMART-1 trial, vasomotor 
effects were assessed in a subset of women from the overall 
study population who had at least seven moderate-to-severe 
hot flushes per day (or $50 per week) at baseline (n = 216).24 
At Week 12, treatment with all doses of BZA/CE significantly 
reduced the mean daily number of moderate and severe hot 
flushes from baseline (range, −51.7% to −85.7%) compared 
with placebo (−17.1%; P , 0.05). The mean change in hot 
flush severity from baseline to Week 12 was reduced for all 
doses of BZA/CE compared with placebo. These reductions 
were significant (P , 0.001) for BZA 10 and 20 mg/CE 0.45 
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Table 1 Study designs for Phase III clinical trials of BZA/CE
SMART-124–27 SMART-228 SMART-329
Duration 2 years 12 weeks 12 weeks
Design Randomized, double-blind, placebo-controlled, Phase III study
Treatments BZA 10, 20, or 40 mg/Ce 0.45  
or 0.625 mg 
RLX 60 mg 
Placebo
BZA 20 mg/Ce 0.45  
or 0.625 mg 
Placebo
BZA 20 mg/Ce 0.45  
or 0.625 mg 
BZA 20 mg 
Placebo
Enrolled Healthy, postmenopausal women with an intact uterus
Aged 40–75 years Aged 40–65 years 
$7 moderate-to-severe  
hot flushes per day  
(or $50 per week)
Aged 40–65 years 
$1 moderate-to-severe 
symptom of vvA
Primary endpoints Incidence of  
endometrial hyperplasia
Frequency/severity  
of hot flushes
Four coprimary measures  
of vvA (proportion of vaginal 
superficial cells, proportion  
of parabasal cells, vaginal pH,  
most bothersome symptom)
Secondary endpoints BMD, BTM,  
frequency/severity of  
hot flushes, measures  
of vvA, sleep, QoL
Sleep, QoL Sexual function, satisfaction  
with treatment, QoL
Abbreviations: BZA, bazedoxifene; Ce, conjugated estrogens; SMART, Selective estrogens, Menopause, And Response to Therapy; RLX, raloxifene; vvA, vulvar vaginal 
atrophy; BMD, bone mineral density; BTM, bone turnover markers; QoL, quality of life.
and 0.625 mg. The significant treatment effects on hot flush 
frequency and severity with BZA 10 and 20 mg/CE 0.45 and 
0.625 mg were maintained through 2 years.24
The SMART-2 trial evaluated the efficacy of VMS 
on a larger population of symptomatic women (n = 332). 
At Week 12,28 treatment with BZA 20 mg/CE 0.45 and 
0.625 mg significantly reduced the number of hot flushes 
from baseline by 74% and 80%, respectively, compared to 
51% with placebo (P , 0.001; Figure 1). The mean daily 
hot flush severity was also significantly reduced for BZA 
20 mg/CE 0.45 and 0.625 mg compared with placebo at Week 
12 (P , 0.001). With BZA 20 mg/CE 0.45 and 0.625 mg, 
61% and 73% of women, respectively, had a 75% or greater 
decrease in the mean number of hot flushes than those treated 
with placebo (27%; P , 0.001) at Week 12.28
effects on vvA
The efficacy of BZA/CE in treating VVA symptoms was 
evaluated by changes in the degree of maturation of the 
vaginal epithelium, measured by the proportion of superficial, 
intermediate, and parabasal cells on a vaginal smear.24 In the 
SMART-1 trial, VVA was assessed in a subset of women 
from the overall study population who had no more than 
5% superficial cells at baseline (n = 1867).24 At Month 24, 
BZA 10 and 20 mg/CE 0.45 and 0.625 mg were associated 
with a significant increase in superficial cells compared with 
placebo (P , 0.001 for BZA 10 mg/CE 0.45 and 0.625 mg; 
P , 0.01 for BZA 20 mg/CE 0.625 mg). There was a 
significant increase in intermediate cells and a significant 
decrease in parabasal cells with BZA 10 and 20 mg/CE 
0.45 and 0.625 mg compared with placebo (P , 0.001 for 
all). BZA 10 mg/CE 0.625 mg and BZA 20 mg/CE 0.45 
and 0.625 mg were also associated with a lower incidence 
of dyspareunia (defined as pain during sexual intercourse) 
than placebo (P , 0.05) during Weeks 9 to 12.24
Similar to the subset within the SMART-1 trial, the 
SMART-3 trial enrolled women with at least one moderate-
to-severe VVA symptom. BZA 20 mg/CE 0.45 and 0.625 mg 
significantly increased superficial cells (P # 0.001), decreased 
parabasal cells (P # 0.001), and increased intermediate cells 
(P , 0.01 for BZA 20 mg/CE 0.45 mg; P # 0.001 for BZA 
20 mg/CE 0.625 mg) compared with placebo at 12 weeks.29 
Mean vaginal pH significantly decreased from baseline to 
Week 12 for both doses of BZA/CE (P , 0.001). With BZA 
20 mg/CE 0.625 mg, but not BZA 20 mg/CE 0.45 mg, severity 
scores for the vaginal symptom originally identified by each 
woman as the most bothersome were significantly improved 
at Week 12 compared with placebo (P = 0.048). At Week 12, 
81% of women treated with BZA 20 mg/CE 0.625 mg and 78% 
of women treated with BZA 20 mg/CE 0.45 mg had responded 
to treatment (defined as vaginal superficial cells .5%, vaginal 
pH ,5, and/or improvement from baseline in most bothersome 
vaginal symptom) compared with 66% of women given 
placebo (P = 0.005 and P = 0.027, respectively).29
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Bone effects
The efficacy of BZA/CE in preventing bone loss was 
evaluated by changes in BMD as measured by dual-energy 
X-ray absorptiometry; changes in bone turnover markers 
(surrogate markers of bone formation and bone resorption) 
were also assessed. Although there has been some variability 
associated with bone turnover marker measurements, these 
markers are widely used to evaluate bone metabolism and 
treatment response to bone-active therapies.30 Effects on BMD 
were evaluated in two substudies within the SMART-1 trial, 
in women who were between 1 and 5 years since menopause 
(YSM) and in those who were greater than 5 YSM. All doses 
of BZA/CE significantly increased lumbar spine and total hip 
BMD compared with placebo at 2 years in the SMART-1 
trial (P , 0.001 for lumbar spine for all women, P , 0.01 
for total hip in women 1–5 YSM, and P , 0.001 for total 
hip in women .5 YSM; Figure 2).26
Changes from baseline in C-telopeptide and osteocalcin 
were measured in women who were between 1 and 
5 YSM. At 2 years, the median percent change in levels of 
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Figure 1 The mean daily number (A) and severity (B) of moderate-to-severe hot flushes over 12 weeks in the SMART-2 trial. 
Copyright © 2009, wolters Kluwer Health. Reprinted with permission from Pinkerton Jv, Utian wH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms 
with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16(6):1116–1124. 
Abbreviations: SMART, Selective estrogens, Menopause, And Response to Therapy; BZA, bazedoxifene; Ce, conjugated estrogens.
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Figure 2 (Continued)
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Figure 2 Adjusted mean percent change in BMD from baseline over 2 years in the SMART-1 trial. 
Copyright © 2009, elsevier. Reprinted with permission from Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. efficacy of tissue-selective estrogen complex of 
bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92:1045–1052. 
Notes: Lumbar spine BMD was evaluated for women .5 YSM (A), or between 1 and 5 YSM (B); total hip BMD was evaluated for women .5 YSM (C), or between 1 and 
5 YSM (D). 
Abbreviations: BMD, bone mineral density; SMART, Selective estrogens, Menopause And Response to Therapy; YSM, years since menopause; BZA, bazedoxifene; Ce, 
conjugated estrogens; RLX, raloxifene.
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C-telopeptide (range, −42.72% to −53.40%) and osteocalcin 
(range, −19.78% to −28.05%) with all doses of BZA/CE were 
significantly reduced compared with placebo (−13.81% and 
3.08%, respectively; P , 0.001 for all).26
Safety
Endometrial safety
In the SMART-1 trial, endometrial safety was assessed   
by the incidence of endometrial hyperplasia, which has 
been used as a surrogate marker for endometrial cancer.27 
In the SMART-1 trial, endometrial biopsy results showed 
one case of endometrial hyperplasia (0.32%) with BZA 
20 mg/CE 0.625 mg and no cases with BZA 20 mg/CE 
0.45 mg or BZA 40 mg/CE 0.45 or 0.625 mg at 1 year. These 
hyperplasia rates were not significantly different from   placebo 
or RLX 60 mg. With BZA 10 mg/CE 0.45 and 0.625 mg, there 
were three cases (0.94%) and 13 cases (3.81%) of endome-
trial hyperplasia, respectively. The 3.81% rate of endometrial 
hyperplasia with BZA 10 mg/CE 0.625 mg was determined 
to be unacceptable per study   criteria.27 As a result, further 
investigations of BZA/CE have focused on doses of BZA 
20 mg/CE 0.45 and 0.625 mg.
Breast safety
High mammographic breast density has been shown to be 
a moderate independent risk factor for breast cancer.31,32 
The effects of BZA/CE on age-related changes in mammo-
graphic breast density were evaluated in an ancillary study 
of the SMART-1 trial. Findings showed that the change 
in baseline breast density was similar for BZA 20 mg/CE 
0.45 mg (−0.39%), BZA 20 mg/CE 0.625 mg (−0.05%), 
RLX 60 mg (−0.23%), and placebo (−0.42%) over 2 years of 
treatment.33 The incidence of breast cancer in the SMART-1 
trial was low and similar for BZA 20 mg/CE 0.45 mg (n = 1), 
BZA 20 mg/CE 0.625 mg (n = 0), and placebo (n = 1) over 
2 years.34 There was no significant difference in the incidence 
of abnormal mammograms for BZA 20 mg/CE 0.45 mg 
(4.4%), BZA 20 mg/CE 0.625 mg (4.2%), and placebo 
(2.6%).35,34 In a pooled analysis of data from the SMART-1, 
SMART-2, and SMART-3 trials, the incidence of breast-
related adverse events (AEs) was low (,0.3%) and similar 
for BZA 20 mg/CE 0.45 mg and placebo (BZA 20 mg/CE 
0.625 mg was not included in this analysis).35 There were 
no reports of fibrocystic breast disease or breast mass with 
BZA 20 mg/CE 0.45 mg or placebo in these three trials.35 
Together, these results suggest that BZA/CE has a neutral 
effect on the breast.
General safety and tolerability
Among all the SMART trials, the overall incidence of 
treatment-emergent AEs was similar among groups.24,28,29 
There were no significant differences between the BZA/CE 
and placebo groups in the percentage of women reporting 
breast pain in the SMART-1, SMART-2, and SMART-3 
trials.24,28,29 In the SMART-1 trial, BZA 20 mg/CE 0.45 and 
0.625 mg were associated with low rates of bleeding/spotting 
and high rates of amenorrhea over consecutive 4-week cycles 
(.83% during Cycles 1–13 and .93% during Cycles 10–13 
during Year 1), with no significant differences compared 
with placebo.25
venous thromboembolic events
In the SMART-1 trial, the incidence of venous thromboem-
bolic events (VTEs) was 0.75 per 1000 woman-years for 
the combined BZA/CE treatment groups compared with 
1.56 per 1000 woman-years for the placebo group (relative 
risk, 0.48; 95% confidence interval, 0.05–4.66). These VTEs 
included one report of deep vein thrombosis in each of the 
BZA 10 mg/CE 0.625 mg and BZA 40 mg/CE 0.625 mg 
groups and one case of deep vein thrombosis in the placebo 
group, as well as one case of pulmonary embolism with 
BZA 40 mg/CE 0.625 mg.24 No VTEs were reported in the 
SMART-2 or SMART-3 trials, but these studies were of 
12-week duration.28,29
Lipid and coagulation parameters
Lipids
Women may experience adverse changes to the metabolic 
profile during the menopausal transition, including 
increases in total cholesterol, triglycerides, low-density 
lipoprotein (LDL) cholesterol, and lipoprotein (a) and 
decreases in high-density lipoprotein (HDL) cholesterol.36 
The effects of BZA/CE on lipid parameters were   evaluated 
in the SMART-1 trial. At Month 24, BZA 20 mg/CE 0.45 
and 0.625 mg were associated with decreases from baseline 
in total cholesterol (P , 0.05 vs placebo for BZA 20 mg/
CE 0.45 mg) and LDL cholesterol (P , 0.01 vs placebo for 
both). HDL cholesterol increased from baseline (P , 0.01 
vs placebo) with BZA 20 mg/CE 0.45 and 0.625 mg, 
as did triglyceride (P , 0.01), HDL-2   cholesterol 
(P , 0.001), and apolipoprotein A1 (P , 0.001)   levels 
compared with placebo. BZA 20 mg/CE 0.45 and 0.625 
also showed significant decreases from baseline in 
  apolipoprotein B (P , 0.05) and lipoprotein (a) (P , 0.01) 
versus placebo.24
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At Week 12 of the SMART-2 trial, both doses of BZA/CE 
were associated with significant decreases from baseline 
compared with placebo in total and LDL cholesterol. HDL 
cholesterol decreased from baseline over 12 weeks with 
placebo, but was maintained at baseline levels with BZA/
CE. Triglyceride levels significantly increased from baseline 
with BZA 20 mg/CE 0.45 and 0.625 mg and with placebo. 
The increase in triglycerides was clinically important for 
more women in the placebo group than in either BZA/CE 
group (P = 0.04).28
Both doses of BZA/CE were associated with significant 
decreases in LDL cholesterol (P , 0.01) at Week 12 in the 
SMART-3 trial. BZA 20 mg/CE 0.625 mg showed a small 
increase in triglyceride levels that was statistically significant 
compared with placebo (P , 0.05).29
Coagulation parameters
Changes in coagulation factors have been shown to occur 
during the menopausal transition, such as increases in levels 
of the coagulation proteins factor VII and fibrinogen.36 The 
effects of BZA/CE on coagulation parameters were evaluated 
in the SMART-1 trial. At Month 24, there were significant 
decreases from baseline in levels of fibrinogen (P , 0.001), 
protein S activity (P , 0.01), and antithrombin III activity 
(P , 0.05 and P , 0.01) for BZA 20 mg/CE 0.45 and 
0.625 mg compared with placebo.24 Neither dose of BZA/CE 
affected partial thromboplastin time, prothrombin time, or 
D-dimer levels. There were small decreases from baseline 
with BZA 20 mg/CE 0.45 and 0.625 mg in plasminogen 
activator inhibitor-1 activity (P , 0.05 for both doses) and 
plasminogen activator inhibitor-1 antigen levels (P , 0.05 
for BZA 20 mg/CE 0.625 mg). Plasminogen activity was 
significantly increased from baseline with BZA 20 mg/CE 
0.45 and 0.625 mg (P , 0.001).24
Sleep, QoL, and satisfaction
During menopause, many women experience bothersome 
symptoms such as VMS, mood disturbances, or sexual 
dysfunction, which may negatively impact QoL.7 Sleep 
disruptions, including increased time to fall asleep, night-
time awakenings, and daytime tiredness, are also common 
among postmenopausal women.37 The effects of BZA/CE on 
sleep parameters were evaluated in the SMART-1 trial using 
daily diaries and in the SMART-2 trial using the Medical 
Outcomes Study sleep scale. Impact on QoL measures 
was assessed in each SMART trial using the Menopause-
specific Quality Of Life (MENQOL) questionnaire. In the 
SMART-3 trial, effects on sexual function were assessed 
using the   Arizona Sexual Experiences scale. Satisfaction with 
treatment was evaluated in the SMART-2 and SMART-3 
trials as measured by the Menopause Symptoms Treatment 
  Satisfaction Questionnaire.
Sleep
In the SMART-1 trial, women treated with BZA 20 mg/
CE 0.45 and 0.625 mg had significant reductions in 
mean minutes to fall asleep (−11.6 and −10.9 minutes, 
respectively), increases in mean minutes slept (22.6 and 
19.7 minutes, respectively), and increases in quality of 
sleep score (0.29 and 0.27, respectively) compared with 
placebo (−5.6 minutes, 10.1 minutes, and 0.13, respectively; 
P , 0.05) at 13 weeks.38 In a subset of women who had at least 
seven hot flushes per day at baseline (n = 81), BZA 20 mg/CE 
0.45 and 0.625 mg improved mean minutes slept and quality 
of sleep score, but did not affect time to fall asleep (this 
analysis was not powered to show statistical significance).38 
In the SMART-2 trial, BZA 20 mg/CE 0.45 and 0.625 mg 
significantly improved time to fall asleep, sleep disturbance, 
sleep adequacy, and overall sleep problems indexes I and II 
compared with placebo (P , 0.001 for all) at 12 weeks in 
the SMART-2 trial as assessed on the Medical Outcomes   
Study sleep scale.39
QoL
At Week 12 in the SMART-1 trial, BZA 20 mg/CE 0.45 
and 0.625 mg significantly improved total (−0.7 and −0.8, 
respectively) and vasomotor function (−1.2 and −1.5, 
respectively) MENQOL scores compared with placebo 
(−0.5 for both domains; P , 0.001).40 Similar results were 
observed in the SMART-2 trial in which BZA 20 mg/CE 
0.45 and 0.625 mg significantly improved total (−1.6 and 
−1.9, respectively) and vasomotor function (−3.3 and −3.8, 
respectively) MENQOL scores compared with placebo (−1.0 
and −1.6, respectively; P , 0.001).39,40 In the SMART-3 
trial, women treated with BZA 20 mg/CE 0.45 and 0.625 mg 
reported significant improvements in ease of lubrication on 
the Arizona Sexual Experiences scale (−0.82 and −0.85, 
respectively) compared with placebo (−0.50; P , 0.05). 
BZA 20 mg/CE 0.45 and 0.625 mg were also associated 
with significant improvements from baseline in the total 
(−1.09 and −1.18, respectively), vasomotor (−1.33 and −1.67, 
respectively), and sexual (−1.95 and −1.91, respectively) 
function compared with placebo (−0.67, −0.51, and −1.24, 
respectively; P , 0.001 for all).41
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Treatment satisfaction
In the SMART-2 trial, Menopause Symptoms Treatment 
  Satisfaction Questionnaire results showed that 73.5% of 
women treated with BZA 20 mg/CE 0.45 mg and 78.2% 
of women treated with BZA 20 mg/CE 0.625 mg were 
satisfied with treatment compared with 44.4% of women 
given   placebo (P , 0.001). In particular, women treated 
with BZA 20 mg/CE 0.45 and 0.625 mg showed significantly 
higher satisfaction than those given placebo in the categories 
of ability to control hot flushes during the day (P , 0.001) 
and during the night (P , 0.001), effect on quality of sleep 
(P , 0.001), and effect on mood and emotions (P , 0.05).39 
Similarly, in the SMART-3 trial, 62.6% of women treated 
with BZA 20 mg/CE 0.45 mg and 69.4% of women treated 
with BZA 20 mg/CE 0.625 mg were satisfied with treatment 
compared with 47.5% of women given placebo (P , 0.05 and 
P , 0.001, respectively). Significantly greater proportions of 
women treated with BZA 20 mg/CE 0.45 and 0.625 mg were 
satisfied with their ability to control hot flushes during the 
day (P , 0.001) and during the night (P , 0.001), effect on 
mood or emotions (P , 0.05), and effect on quality of sleep 
(P , 0.001) compared with placebo at 12 weeks.41
Conclusion
The TSEC is a novel menopausal therapy that has been devel-
oped to blend the uterine- and breast-protective effects of a 
SERM in women with a uterus with the established benefits 
of estrogens on VMS, VVA, and bone. TSECs, such as BZA/
CE, may be an appropriate alternative to HT for women with 
concerns about the potential safety risks of HT (combined 
estrogen/progestin or estradiol/progestin therapy) such as car-
diovascular risk and breast stimulation.11,14,15   Tolerability con-
cerns include breast pain and irregular vaginal bleeding.11
Preclinical studies showed that BZA/CE has favorable 
vasomotor effects and prevents bone loss in OVX rats 
while minimizing stimulation of uterine and breast tissue in 
a variety of in vitro and in vivo models. Furthermore, the 
tissue-selective effects of BZA/CE were distinct from those 
of RLX/CE or LAS/CE. BZA was shown to be a stronger 
antagonist of CE-induced breast cancer cell proliferation 
and mammary gland end bud formation than RLX or LAS. 
BZA and RLX were more effective in inhibiting CE-induced 
increases in uterine wet weight than was LAS.
In Phase III clinical studies, BZA 20 mg/CE 0.45 and 
0.625 mg were shown to significantly reduce the frequency/
severity of hot flushes and improve VVA measures in 
symptomatic postmenopausal women. These BZA/CE 
doses also significantly increased BMD at the lumbar spine 
and total hip while preventing endometrial stimulation, as 
shown by low rates of endometrial hyperplasia similar to 
those with placebo.
Results of the SMART trials showed that treatment with 
BZA 20 mg/CE 0.45 and 0.625 mg maintained breast safety, 
with low rates of breast-related AEs and no changes in breast 
density. In contrast, HT use has been reported to increase 
mammographic breast density,42–44 and long-term estrogen 
plus progestin therapy has been associated with an increased 
risk of breast cancer.11 Study findings also showed that BZA/
CE has a favorable tolerability profile, with incidences of 
bleeding/spotting and breast tenderness that were low and 
similar compared with placebo. These results contrast those 
reported for HT, which has been associated with increased 
rates of bleeding/spotting as well as breast pain/tenderness 
compared with placebo.45 BZA/CE also showed positive 
effects on coagulation factors and improvements in lipid 
parameters in the SMART trials, including decreases in 
total and LDL cholesterol and increases in HDL cholesterol. 
These effects on blood lipids with BZA/CE have been shown 
to be similar to those observed with CE alone and with   
CE/MPA.46
BZA/CE has demonstrated significant improve-
ments in sleep parameters, including time to fall asleep 
and overall sleep scores. Studies of HT have also shown 
improvements in sleep, although the effects were relatively 
small.47–50 BZA/CE also showed significant improvements 
in total and vasomotor   function in all three SMART trials; 
in comparison, the effects of HT on QoL parameters have 
been mixed.47,48,51–53
Overall, BZA/CE has been shown to be generally safe 
and well tolerated over 2 years of treatment in   postmenopausal 
women and is associated with high rates of treatment 
satisfaction. Collectively, these data suggest that BZA/CE 
is a   promising option for the comprehensive treatment of 
menopausal symptoms and prevention of postmenopausal 
osteoporosis. Further studies are needed to determine the 
long-term efficacy and safety of BZA/CE in postmenopausal 
women.
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